Vivek Ra­maswamy's LNP de­liv­ery tech play Genevant scores $600M li­cens­ing deal from Take­da for nu­cle­ic acid ther­a­pies

With mR­NA vac­cines in high de­mand and new RNA ther­a­peu­tics crowd­ing on­to the mar­ket, the de­mand for lipid nanopar­ti­cles has nev­er been high­er. Now, one of se­r­i­al en­tre­pre­neur Vivek Ra­maswamy’s Vant out­fits has scored a big deal with Take­da to de­vel­op LNP-de­liv­ered liv­er drugs.

The Japan­ese drug­mak­er will ear­mark $600 mil­lion for a li­cens­ing deal with Genevant, an LNP de­liv­ery tech out­fit, to de­vel­op nu­cle­ic acid ther­a­pies for liv­er fi­bro­sis, the com­pa­nies said Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER